Hemab Therapeutics Holdings, Inc.
CIK:
0002114044
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
other
State of Incorporation
DE
Business Address
101 MAIN STREET, CAMBRIDGE, MA, 02142
Mailing Address
101 MAIN STREET, CAMBRIDGE, MA, 02142
Phone
45 2138 7627
Fiscal Year End
1231
EIN
414241952
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-1 IPO registration statement | April 10, 2026 | View on SEC |
IPO Filings
S-1
April 10, 2026
- Developing a 'coagulation franchise' with a clear 2x3 by 2030 commercial roadmap.
- Lead drug Sutacimig (HMB-001) targets the underserved Glanzmann thrombasthenia market.
Related Companies
Companies in the same industry (SIC: 2836)
MESOBLAST LTD
MESO
Biological Products, (No Diagnostic Substances)
Quince Therapeutics, Inc.
QNCX
Biological Products, (No Diagnostic Substances)
Kymera Therapeutics, Inc.
KYMR
Biological Products, (No Diagnostic Substances)
Scilex Holding Co
SCLX
Biological Products, (No Diagnostic Substances)
Vor Biopharma Inc.
VOR
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.